Uniseed Ventures
VC Fund
Brisbane, Australia
Uniseed Ventures is a VC fund in Brisbane focused on Biotechnology and Health Care. Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
- Total investments:
- 57
- Last investment:
- Lead investor:
- 12%
- Fund size:
- $14M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Uniseed Ventures invests in
Stages Uniseed Ventures invests in
Countries Uniseed Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $381k–$4.2M
- Series A
- $1.3M–$16M
Investment Focus
Industry
- Biotechnology 16 (28%)
- Health Care 7 (12%)
- Manufacturing 7 (12%)
- Biopharma 6 (11%)
- Medical 5 (9%)
Stage
- Series A 17 (30%)
- Seed 11 (19%)
- Funding Round 9 (16%)
- Series B 7 (12%)
- Series C 3 (5%)
Country
- Australia 29 (51%)
- United States 3 (5%)
- United Kingdom 2 (4%)
- India 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Allan Tait
Director
|
Director | Total investments: 0 | Find email | |
Anthony Musumeci
Investment Manager
|
Investment Manager | Total investments: 6 | Find email | |
|
Duncan Ivison
Director
|
Director | Total investments: 0 | Find email | |
|
Jack Steele
Director
|
Director | Total investments: 0 | Find email | |
John Green
Company Secretary
|
Company Secretary | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BioScout
|
BioScout utilises state-of-the-art technology to detect and prevent airborne diseases allowing for proactive disease management on farms worldwide! | $685.5K / Seed / May 29, 2023 | |
Ferronova
|
Ferronova is a medical device company that offers imaging and surgery products. | $5.1M / Series B / Jan 22, 2023 | |
Morse Micro
|
Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com | $20M / Series B / Nov 28, 2022 | |
Tiny Bright Things
|
Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent). | $1.5M / Seed / Nov 03, 2022 | |
|
Morse Micro
|
Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com | $94.2M / Series B / Sep 06, 2022 | |
Forcite Helmet Systems
|
A common conception is that motorcycling is dangerous. And to a certain extent, this is true. In contrast to modern cars, motorcycles lack standard safety equipment such as advanced driver warning and anti-collision systems. Forcite was borne to remedy and bridge this blatant gap: our helmet and software systems make motorcycling 10x safer.Sensor tech, the Forcite Command software platform and lightweight carbon fiber provide the basis for this disruptive technology. Take a look under the visor and learn more about what we have in store. | $4.1M / Series A / Feb 10, 2022 | |
Currus Biologics
|
Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers. | $7.5M / Series A / Jun 29, 2021 | |
Ena Respiratory
|
Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $24.2M / Venture - Series Unknown / Jun 17, 2021 | |
|
Ena Respiratory
|
Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $7.6M / Series A / Sep 28, 2020 | |
|
Ferronova
|
Ferronova is a medical device company that offers imaging and surgery products. | $2.3M / Series A / May 25, 2020 | |
| See all 57 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Uniseed Ventures invest in?
Uniseed Ventures invests primarily in Biotechnology, Health Care and Manufacturing startups, most often at Series A and Seed stage. Most of the 57 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Uniseed Ventures's check size?
Uniseed Ventures typically joins rounds of $381k–$4.2M at Seed and $1.3M–$16M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Uniseed Ventures participates in.
How do I contact Uniseed Ventures?
Public channels for Uniseed Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Uniseed Ventures?
The team at Uniseed Ventures includes Allan Tait (Director), Anthony Musumeci (Investment Manager) and Duncan Ivison (Director), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
